GlassScriptPhysician profile
James Henry Reed
NPI 1851451934
$1,551.37
in general payments reported to CMS, 2019-2025
17 companies · $144 in 2025
The $144 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $153 · 2022: $59.31 · 2023: $165 · 2024: $230 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $520 · Education: $19.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.96 |
| Education | $19.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $251.29 | 2019-2025 | |
| Gilead Sciences, INC. | $208.08 | 2019-2020 | |
| Pfizer INC. | $172.66 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $145.01 | 2019-2024 | Entyvio, Eohilia |
| Qol Medical, LLC | $141.41 | 2022-2024 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $122.67 | 2019 | |
| Medtronic, INC. | $92.74 | 2024-2025 | Gi Genius |
| Braintree Laboratories, INC. | $84.32 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.61 | 2019 | |
| Lilly USA, LLC | $64.75 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $47.25 | 2024 | Vegzelma, Zymfentra |
| Janssen Biotech, INC. | $46.57 | 2020-2023 | Remicade, Simponi Aria, Simponi |
| Allergan, INC. | $27.87 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.79 | 2023 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $20.36 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $18.39 | 2019 | |
| Novo Nordisk INC | $17.60 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.